Annual report for Fortis Healthcare Ltd. for FY-2019
25-05-2019
FORTIS HEALTHCARE LTD. - 532843 - Outcome of Board Meeting
Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. on May 24, 2019, inter-alia, considered and approved: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2019. M/s. B S R & Co. LLP, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on Impact of Modified Opinion thereon; 2. Appointment of M/s B S R & Co. LLP, Chartered Accountants (Registration No. 101248W/W-100022) as Statutory Auditor of the Company to hold such office until the conclusion of twenty eighth (28th) Annual General Meeting to be held in year 2024, subject to the approval of shareholders of the Company in the ensuing Annual General Meeting;24-05-2019
Fortis Healthcare International to sell stake in MSCL
Mauritius-based Fortis Healthcare International holds 28.89 per cent stake in MSCL.18-05-2019
Fortis Healthcare Ltd - 532843 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Fortis Healthcare International Limited ('FHIL'), a wholly owned subsidiary of Fortis Healthcare Limited ('FHL' or 'the Company'), which is incorporated in Mauritius, has entered into a share purchase agreement ('SPA') with CIEL Limited, CIEL Healthcare Limited (collectively referred to as 'CIEL') and The Medical and Surgical Centre Limited ('MSCL'), for, inter alia, sale of the entire shareholding held by FHIL in MSCL, representing 28.89% (164,670,801 shares) holding of the total issued and paid up equity share capital of MSCL ('Proposed Transaction'). The Proposed Transaction is subject to the approval of FHL's shareholders as well as regulatory approval, if required. Upon consummation of the Proposed Transaction, the entire stake of FHIL in MSCL will be divested. The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith as Annexure A.17-05-2019
Fortis Healthcare Ltd - 532843 - Board Meeting Intimation for Notice Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2019 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, May 24, 2019 to, inter-alia, consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2019. Further, in continuation to our letter ref. FHL/SEC/2018-19 dated March 29, 2019 captioned 'Disclosure under Regulation 30 - Closure of Trading Window', it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till May 26, 2019 and will re-open from May 27, 2019. This is for your information and record please.17-05-2019
Fortis Healthcare Ltd - 532843 - Disclosure Under Regulation 30- Trading Approval
This is in continuation of our intimation made vide ref. no FHL/SEC/2018-19 dated January 3, 2019 captioned 'Disclosure under Regulation 30- Trading Approval', with respect to preferential allotment of 23,52,94,117 Equity Shares to Northern TK Venture Pte Ltd. Please note that due to an inadvertent error, a lock-in period of 3 years was indicated as being applicable to the entirety of the 235,294,117 allotted equity shares. The same has been rectified on May 15, 2019 in compliance with Regulation 167(1) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and the details of which are set out hereafter: Sn. Number of Securities Date up to which lock-in 1. 150,990,390 03-Jan-2022 2. 84,303,727 03-Jan-2020 This is for your information and records please.16-05-2019
M&A; deals in hospital sector hit a five-year high, says Icra report
The two largest transactions involving the acquisition of stakes in two listed entities - Fortis Healthcare (Rs 4,000 crore) and Max Healthcare (Rs 2,351 crore)06-05-2019
Fortis Healthcare Ltd - 532843 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayFORTIS HEALTHCARE LTD. 2CININE061F01013 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 356 4Highest Credit Rating during the previous FY BBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Sumit Goel Designation: Company Secretary & Compliance Officer EmailId: secretarial@fortishealthcare.com Name of the Chief Financial Officer: Vivek Kumar Goyal Designation: Chief Financial Officer EmailId: secretarial@fortishealthcare.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2019
FORTIS HEALTHCARE LTD. - 532843 - Disclosure Under Securities And Exchange Board Of India Circular Ref. No. SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 ('SEBI Circular')
This is with reference to the above SEBI Circular dated 26 November 2018, please note that as on the last day of financial year i.e. on March 31, 2019, we would like to inform you that Fortis Healthcare Limited is not identified as 'Large Corporate' as per the framework provided in the aforesaid Circular. This is for your information and records please.30-04-2019
FORTIS HEALTHCARE LTD. - 532843 - Shareholding for the Period Ended March 31, 2019
Fortis Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here16-04-2019